PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27862969-7 2017 We suggest that hypothalamic ghrelin signaling system, with the help of antioxidants, may participate in NPY/CART-mediated appetite control in PPA-treated rats. Phenylpropanolamine 143-146 neuropeptide Y Rattus norvegicus 105-108 23707533-1 2013 Neuropeptide Y (NPY) and nuclear factor-kappa B (NF-kappaB) are involved in regulating anorexia elicited by phenylpropanolamine (PPA), a sympathomimetic drug. Phenylpropanolamine 108-127 neuropeptide Y Rattus norvegicus 16-19 24792324-7 2015 Moreover, cerebral STAT3 knockdown modified PPA-induced anorexia and antioxidants, POMC, and NPY expression. Phenylpropanolamine 44-47 neuropeptide Y Rattus norvegicus 93-96 23707533-1 2013 Neuropeptide Y (NPY) and nuclear factor-kappa B (NF-kappaB) are involved in regulating anorexia elicited by phenylpropanolamine (PPA), a sympathomimetic drug. Phenylpropanolamine 129-132 neuropeptide Y Rattus norvegicus 16-19 23052195-0 2013 Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats. Phenylpropanolamine 117-136 neuropeptide Y Rattus norvegicus 0-14 23052195-1 2013 It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression. Phenylpropanolamine 148-167 neuropeptide Y Rattus norvegicus 49-63 23052195-1 2013 It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression. Phenylpropanolamine 148-167 neuropeptide Y Rattus norvegicus 65-68 23052195-1 2013 It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression. Phenylpropanolamine 169-172 neuropeptide Y Rattus norvegicus 49-63 23052195-1 2013 It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression. Phenylpropanolamine 169-172 neuropeptide Y Rattus norvegicus 65-68 23052195-8 2013 These results suggest that Y1R participates in the reciprocal regulation of NPY, GP, and CREB in the hypothalamus during PPA treatment in conscious rats. Phenylpropanolamine 121-124 neuropeptide Y Rattus norvegicus 76-79 19183253-0 2009 Roles of protein kinase Calpha isozyme in the regulation of oxidative stress and neuropeptide Y gene expression in phenylpropanolamine-mediated appetite suppression. Phenylpropanolamine 115-134 neuropeptide Y Rattus norvegicus 81-95 23179670-0 2013 The identification of neuropeptide Y receptor subtype involved in phenylpropanolamine-induced increase in oxidative stress and appetite suppression. Phenylpropanolamine 66-85 neuropeptide Y Rattus norvegicus 22-36 23179670-1 2013 Hypothalamic neuropeptide Y (NPY) and superoxide dismutase (SOD) have been reported to participate in the regulation of appetite-suppressing effect of phenylpropanolamine (PPA), a sympathomimetic agent. Phenylpropanolamine 151-170 neuropeptide Y Rattus norvegicus 0-33 23179670-1 2013 Hypothalamic neuropeptide Y (NPY) and superoxide dismutase (SOD) have been reported to participate in the regulation of appetite-suppressing effect of phenylpropanolamine (PPA), a sympathomimetic agent. Phenylpropanolamine 172-175 neuropeptide Y Rattus norvegicus 0-33 21989786-1 2012 It has been reported that oxidative stress, antioxidants, and neuropeptide Y (NPY) are involved in regulating the feeding behavior of phenylpropanolamine (PPA), a sympathomimetic drug. Phenylpropanolamine 134-153 neuropeptide Y Rattus norvegicus 62-76 21989786-1 2012 It has been reported that oxidative stress, antioxidants, and neuropeptide Y (NPY) are involved in regulating the feeding behavior of phenylpropanolamine (PPA), a sympathomimetic drug. Phenylpropanolamine 134-153 neuropeptide Y Rattus norvegicus 78-81 21989786-1 2012 It has been reported that oxidative stress, antioxidants, and neuropeptide Y (NPY) are involved in regulating the feeding behavior of phenylpropanolamine (PPA), a sympathomimetic drug. Phenylpropanolamine 155-158 neuropeptide Y Rattus norvegicus 62-76 21989786-1 2012 It has been reported that oxidative stress, antioxidants, and neuropeptide Y (NPY) are involved in regulating the feeding behavior of phenylpropanolamine (PPA), a sympathomimetic drug. Phenylpropanolamine 155-158 neuropeptide Y Rattus norvegicus 78-81 21989786-8 2012 It is suggested that hypothalamic NF-kappaB participates in the reciprocal regulation of NPY and antioxidants, which mediated the appetite-suppressing effect of PPA. Phenylpropanolamine 161-164 neuropeptide Y Rattus norvegicus 89-92 21453188-10 2011 CONCLUSION: Results suggest that ROS-RE/POMC- and NPY-containing neurons function reciprocally in regulating both the anorectic and tolerant effects of PPA, while aPKC is upstream of these regulators. Phenylpropanolamine 152-155 neuropeptide Y Rattus norvegicus 50-53 20533995-1 2010 Hypothalamic neuropeptide Y (NPY) has been reported to involve in regulating behavioral response of phenylpropanolamine (PPA), a sympathomimetic agent. Phenylpropanolamine 100-119 neuropeptide Y Rattus norvegicus 0-33 20533995-1 2010 Hypothalamic neuropeptide Y (NPY) has been reported to involve in regulating behavioral response of phenylpropanolamine (PPA), a sympathomimetic agent. Phenylpropanolamine 121-124 neuropeptide Y Rattus norvegicus 0-33 20533995-6 2010 Results showed that PKCdelta and CAT increased during PPA treatment, which were concomitant with decreases in NPY content and food intake, while the change of NOS was expressed differently. Phenylpropanolamine 54-57 neuropeptide Y Rattus norvegicus 110-113 19183253-2 2009 Although regulation of NPY expression has been reported to contribute to the appetite-suppressing effect of phenylpropanolamine (PPA), it is still unknown if protein kinase C (PKC) is involved in this effect. Phenylpropanolamine 108-127 neuropeptide Y Rattus norvegicus 23-26 19183253-2 2009 Although regulation of NPY expression has been reported to contribute to the appetite-suppressing effect of phenylpropanolamine (PPA), it is still unknown if protein kinase C (PKC) is involved in this effect. Phenylpropanolamine 129-132 neuropeptide Y Rattus norvegicus 23-26 17684035-7 2007 Results also showed that PKA knock-down could block PPA-induced anorexia as well as restore NPY mRNA level, indicating the involvement of PKA signaling in the regulation of NPY gene expression. Phenylpropanolamine 52-55 neuropeptide Y Rattus norvegicus 173-176 17868324-1 2008 The mechanism for phenylpropanolamine (PPA)-induced anorexia has been attributed to its inhibitory action on hypothalamic neuropeptide Y (NPY), an orexigenic agent abundant in the brain. Phenylpropanolamine 18-37 neuropeptide Y Rattus norvegicus 122-136 17868324-1 2008 The mechanism for phenylpropanolamine (PPA)-induced anorexia has been attributed to its inhibitory action on hypothalamic neuropeptide Y (NPY), an orexigenic agent abundant in the brain. Phenylpropanolamine 18-37 neuropeptide Y Rattus norvegicus 138-141 17868324-1 2008 The mechanism for phenylpropanolamine (PPA)-induced anorexia has been attributed to its inhibitory action on hypothalamic neuropeptide Y (NPY), an orexigenic agent abundant in the brain. Phenylpropanolamine 39-42 neuropeptide Y Rattus norvegicus 122-136 17868324-1 2008 The mechanism for phenylpropanolamine (PPA)-induced anorexia has been attributed to its inhibitory action on hypothalamic neuropeptide Y (NPY), an orexigenic agent abundant in the brain. Phenylpropanolamine 39-42 neuropeptide Y Rattus norvegicus 138-141 17684035-0 2007 Transcript of protein kinase A knock-down modulates feeding behavior and neuropeptide Y gene expression in phenylpropanolamine-treated rats. Phenylpropanolamine 107-126 neuropeptide Y Rattus norvegicus 73-87 17684035-1 2007 Neuropeptide Y (NPY) is an appetite-controlling neuromodulator that contributes to the appetite-suppressing effect of phenylpropanolamine (PPA). Phenylpropanolamine 118-137 neuropeptide Y Rattus norvegicus 0-14 17684035-1 2007 Neuropeptide Y (NPY) is an appetite-controlling neuromodulator that contributes to the appetite-suppressing effect of phenylpropanolamine (PPA). Phenylpropanolamine 118-137 neuropeptide Y Rattus norvegicus 16-19 17684035-1 2007 Neuropeptide Y (NPY) is an appetite-controlling neuromodulator that contributes to the appetite-suppressing effect of phenylpropanolamine (PPA). Phenylpropanolamine 139-142 neuropeptide Y Rattus norvegicus 0-14 17684035-1 2007 Neuropeptide Y (NPY) is an appetite-controlling neuromodulator that contributes to the appetite-suppressing effect of phenylpropanolamine (PPA). Phenylpropanolamine 139-142 neuropeptide Y Rattus norvegicus 16-19 18221372-1 2008 The appetite-suppressing effect of phenylpropanolamine (PPA) has been attributed to its inhibitory action on neuropeptide Y (NPY), an appetite stimulant. Phenylpropanolamine 35-54 neuropeptide Y Rattus norvegicus 109-123 18221372-1 2008 The appetite-suppressing effect of phenylpropanolamine (PPA) has been attributed to its inhibitory action on neuropeptide Y (NPY), an appetite stimulant. Phenylpropanolamine 35-54 neuropeptide Y Rattus norvegicus 125-128 18221372-1 2008 The appetite-suppressing effect of phenylpropanolamine (PPA) has been attributed to its inhibitory action on neuropeptide Y (NPY), an appetite stimulant. Phenylpropanolamine 56-59 neuropeptide Y Rattus norvegicus 109-123 18221372-1 2008 The appetite-suppressing effect of phenylpropanolamine (PPA) has been attributed to its inhibitory action on neuropeptide Y (NPY), an appetite stimulant. Phenylpropanolamine 56-59 neuropeptide Y Rattus norvegicus 125-128 15572205-6 2004 Results revealed that PPA treatment in rats could decrease both NPY content and mRNA level in the hypothalamus. Phenylpropanolamine 22-25 neuropeptide Y Rattus norvegicus 64-67 15572205-7 2004 In addition, the expression of NPY immunoreactivity following PPA treatment was decreased in areas of hypothalamic arcuate nucleus, paraventricular nucleus and periventricular area using immunohistochemical staining, suggesting an involvement of NPYergic pathway in the action of PPA anorexia. Phenylpropanolamine 62-65 neuropeptide Y Rattus norvegicus 31-34 15572205-7 2004 In addition, the expression of NPY immunoreactivity following PPA treatment was decreased in areas of hypothalamic arcuate nucleus, paraventricular nucleus and periventricular area using immunohistochemical staining, suggesting an involvement of NPYergic pathway in the action of PPA anorexia. Phenylpropanolamine 280-283 neuropeptide Y Rattus norvegicus 31-34